Eckert & Ziegler SE/€EUZ
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Eckert & Ziegler SE
Eckert & Ziegler SE is a company operating in the pharmaceuticals industry, particularly specializing in the field of medical technology. It focuses on the development, production, and distribution of radioisotopes used for medical imaging, cancer treatment, and industrial applications. Some of its key products include low and high-energy sources used in brachytherapy and calibration sources for imaging devices. Founded in 1997, the company is headquartered in Berlin, Germany. Eckert & Ziegler SE leverages its technical expertise and regulatory experience to deliver specialized solutions, positioning itself as a critical provider in the healthcare and radiation therapy sectors.
Ticker
€EUZ
Sector
Primary listing
XETRA
Employees
1,098
Headquarters
Website
EUZ Metrics
BasicAdvanced
€1.1B
30.72
€0.58
1.56
€0.17
0.94%
Price and volume
Market cap
€1.1B
Beta
1.56
52-week high
€23.25
52-week low
€12.27
Average daily volume
112K
Dividend rate
€0.17
Financial strength
Current ratio
3.037
Quick ratio
2.344
Long term debt to equity
17.555
Total debt to equity
21.489
Dividend payout ratio (TTM)
31.30%
Interest coverage (TTM)
19.05%
Profitability
EBITDA (TTM)
81.7
Gross margin (TTM)
48.59%
Net profit margin (TTM)
12.24%
Operating margin (TTM)
23.24%
Effective tax rate (TTM)
31.29%
Revenue per employee (TTM)
€270,000
Management effectiveness
Return on assets (TTM)
9.55%
Return on equity (TTM)
17.72%
Valuation
Price to earnings (TTM)
30.725
Price to revenue (TTM)
3.72
Price to book
4.82
Price to tangible book (TTM)
6.08
Price to free cash flow (TTM)
19.612
Free cash flow yield (TTM)
5.10%
Free cash flow per share (TTM)
0.908
Dividend yield (TTM)
0.94%
Forward dividend yield
0.94%
Growth
Revenue change (TTM)
9.42%
Earnings per share change (TTM)
8.51%
3-year revenue growth (CAGR)
14.70%
10-year revenue growth (CAGR)
8.36%
3-year earnings per share growth (CAGR)
10.67%
10-year earnings per share growth (CAGR)
12.87%
3-year dividend per share growth (CAGR)
-53.56%
10-year dividend per share growth (CAGR)
-10.39%
Bulls say / Bears say
In the first half of 2025, Eckert & Ziegler’s H1 sales rose 2% to €148.8 million, H1 adjusted EBIT increased 9% to €35.4 million, and net profit climbed 19% to €21.4 million, with the company reaffirming its 2025 outlook of around €320 million in sales and €78 million in adjusted EBIT (Reuters)
Eckert & Ziegler entered a supply agreement with Actinium Pharmaceuticals for Actinium-225, securing high-quality Ac-225 for Actimab-A and development programs in U.S. and international clinical trials (PRNewswire)
In March 2025, the company signed a global supply agreement with AtomVie Global Radiopharma to provide non-carrier-added Lutetium-177 chloride (Theralugand®), bolstering its CDMO partnerships and enhancing revenue visibility across development and commercial programs (PRNewswire)
A cyber-attack in early February 2025 disrupted Eckert & Ziegler’s IT infrastructure, forcing temporary manual processes and risking operational delays despite swift recovery measures (FinanzWire)
A data breach investigation by Strauss Borrelli, following the Feb. 2 2025 unauthorized access to sensitive personal information, exposes the company to potential legal liabilities, regulatory scrutiny, and reputational damage (Strauss Borrelli PLLC)
In H1 2025, the Isotope Products segment saw external sales decline by about 10% to €68.3 million year-on-year due to seasonal shifts and product mix changes, highlighting portfolio concentration risks (FinanzWire)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eckert & Ziegler SE stock?
Eckert & Ziegler SE (EUZ) has a market cap of €1.1B as of September 10, 2025.
What is the P/E ratio for Eckert & Ziegler SE stock?
The price to earnings (P/E) ratio for Eckert & Ziegler SE (EUZ) stock is 30.72 as of September 10, 2025.
Does Eckert & Ziegler SE stock pay dividends?
Yes, the Eckert & Ziegler SE (EUZ) stock pays dividends to shareholders. As of September 10, 2025, the dividend rate is €0.16666 and the yield is 0.94%. Eckert & Ziegler SE has a payout ratio of 31.3% on a trailing twelve-month basis.
When is the next Eckert & Ziegler SE dividend payment date?
The next Eckert & Ziegler SE (EUZ) dividend payment date is unconfirmed.
What is the beta indicator for Eckert & Ziegler SE?
Eckert & Ziegler SE (EUZ) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.